World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
117
Citations
66368
World Ranking
4137
National Ranking
160

Overview

Geert R. D'Haens is affiliated with the University of Amsterdam in the Netherlands and has contributed extensively to medical research, particularly in the field of inflammatory bowel diseases. Their research encompasses a broad range of topics within medicine and related biological sciences.

Their main fields of study include:

  • Medicine
  • Biochemistry, Genetics and Molecular Biology

Within these broader categories, their subfields of study cover areas such as:

  • Genetics
  • Epidemiology
  • Surgery
  • Immunology
  • Oncology

The primary research themes focus largely on inflammatory and autoimmune conditions, with leading topics including:

  • Inflammatory Bowel Disease
  • Microscopic Colitis
  • Eosinophilic Esophagitis
  • Immunodeficiency and Autoimmune Disorders
  • Chronic Lymphocytic Leukemia Research
  • Autoimmune and Inflammatory Disorders
  • Biosimilars and Bioanalytical Methods

They have co-authored multiple publications with frequent collaborators such as Silvio Danese, Séverine Vermeire, Laurent Peyrin-Biroulet, Remo Panaccione, and K Gecse. These collaborations reflect a network of significant contributors in the field of gastroenterology and immunology.

Their work is commonly published in well-known academic venues, which include:

  • Journal of Crohn's and Colitis
  • Gastroenterology
  • The American Journal of Gastroenterology
  • Inflammatory Bowel Diseases
  • Clinical Gastroenterology and Hepatology

Selected recent papers highlight their focus on therapies for inflammatory bowel conditions:

  • Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials, 2022, The Lancet
  • Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials, 2022, The Lancet
  • Ozanimod as Induction and Maintenance Therapy for Ulcerative Colitis, 2021, New England Journal of Medicine
  • Upadacitinib Induction and Maintenance Therapy for Crohn's Disease, 2023, New England Journal of Medicine
  • Efficacy and Safety of Upadacitinib in a Randomized Trial of Patients With Crohn's Disease, 2020, Gastroenterology

Best Publications

  • Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.

    Eric Van Cutsem;Claus Henning Köhne;Erika Hitre;Jerzy Zaluski

  • Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CD

    Marco Daperno;Geert D'Haens;Gert Van Assche;Filip Baert

  • A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis.

    Geert D’Haens;William J. Sandborn;Brian G. Feagan;Karel Geboes

  • Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis

    William J. Sandborn;Chinyu Su;Bruce E. Sands;Geert R. D’Haens

  • Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial

    Geert D'Haens;Filip Baert;Gert van Assche;Philip Caenepeel

  • A simple classification of Crohn's disease: report of the Working Party for the World Congresses of Gastroenterology, Vienna 1998.

    Christoph Gasche;Jurgen Scholmerich;Jorn Brynskov;Geert D'Haens

  • Adalimumab Induces and Maintains Clinical Remission in Patients With Moderate-to-Severe Ulcerative Colitis

    William J. Sandborn;Gert van Assche;Walter Reinisch;Jean–Frederic Colombel

  • Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease.

    Paul Rutgeerts;G D'Haens;S Targan;E Vasiliauskas

  • Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial.

    William J. Sandborn;Paul Rutgeerts;Robert Enns;Stephen B. Hanauer

  • The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Special situations

    Gert Van Assche;Axel Dignass;Walter Reinisch;C. Janneke van der Woude

  • Early Lesions of Recurrent Crohn's Disease Caused by Infusion of Intestinal Contents in Excluded Ileum

    Geert R. D'Haens;Karel Geboes;Mark Peeters;Filip Baert

  • Findings From a Randomized Controlled Trial of Fecal Transplantation for Patients With Ulcerative Colitis

    Noortje G. Rossen;Susana Fuentes;Mirjam J. van der Spek;Jan G. Tijssen

  • Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease

    Geert D'Haens;Marc Ferrante;Severine Vermeire;Filip Baert

  • Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease.

    Filip Baert;Liesbeth Moortgat;Gert Van Assche;Philip Caenepeel

  • Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: A European multicenter trial.

    Geert D'Haens;S Van Deventer;R Van Hogezand;D Chalmers

  • Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn’s disease

    Severine Vermeire;Maja Noman;Gert van Assche;Filip Baert

  • The safety of vedolizumab for ulcerative colitis and Crohn's disease

    Jean Frédéric Colombel;Bruce E. Sands;Paul Rutgeerts;William Sandborn

  • Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial

    Jean Frederic Colombel;Remo Panaccione;Peter Bossuyt;Milan Lukas

  • Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial

    Walter Reinisch;William J Sandborn;Daniel W Hommes;Geert D'Haens

  • Effects of Vedolizumab Induction Therapy for Patients With Crohn’s Disease in Whom Tumor Necrosis Factor Antagonist Treatment Failed

    Bruce E. Sands;Brian G. Feagan;Paul Rutgeerts;Jean Frédéric Colombel;Jean Frédéric Colombel

Frequent Co-Authors

William J. Sandborn
William J. Sandborn University of California, San Diego
Brian G. Feagan
Brian G. Feagan University of Western Ontario
Jean-Frederic Colombel
Jean-Frederic Colombel Icahn School of Medicine at Mount Sinai
Cyriel Y. Ponsioen
Cyriel Y. Ponsioen University of Amsterdam
Remo Panaccione
Remo Panaccione University of Calgary
Walter Reinisch
Walter Reinisch Medical University of Vienna
Julián Panés
Julián Panés University of Barcelona
Silvio Danese
Silvio Danese Vita-Salute San Raffaele University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring a career in Medicine doesn’t always mean becoming a physician. Diverse online degree programs now offer flexible routes to impactful roles in healthcare. For those interested in leadership, affordable mha online programs prepare students for management positions in hospitals and clinics, blending healthcare skills with business acumen.

Nursing professionals aiming to advance their clinical practice can consider the cheapest dnp pathways, helping them reach the highest level of nursing expertise. Similarly, pharmacy is evolving with technology—an online pharmacy degree allows future pharmacists to train while balancing work and life commitments.

Finally, digital healthcare continues to grow rapidly. A health information technology online degree can lead to rewarding roles managing patient data, improving health outcomes, and ensuring privacy.

These online programs provide new pathways into healthcare, opening doors to a range of specialties beyond traditional medical school.

Best Scientists Citing Geert R. D'Haens

Trending Scientists

Recently Published Articles